Combining GCLC inhibition with GLS and CAD inhibitors shows promise as a synergistically lethal treatment for GBM cells, and in vivo experiments support the potential of targeting GSH metabolism in GBM therapy [139]. The gene discussed is GCLC; the disease is glioblastoma.